Detailed analysis of Anamorelin instruction manual

Anamorelin (Anamorelin) is a new oral small molecule drug that belongs to the Ghrelin receptor agonist class. Its core mechanism is to improve the appetite and nutritional metabolic status of cancer patients by stimulating the growth hormone secretion receptor (GHS-R1a). As cancer cachexia (Cancer Cachexia) is regarded as a key syndrome affecting the quality of life and survival rate of patients with advanced cancer, the emergence of anamorelin provides a new way of drug intervention for these patients. The following is a detailed analysis of this drug.

1. [Indications]

The main target of anamorelin isGHS-R1a (growth hormone secretory receptor type 1a), that is, the Ghrelin receptor. This receptor is distributed in the appetite center area of u200bu200bthe hypothalamus. When activated by the drug, it can stimulate appetite, promote energy intake, and improve the patient's metabolic balance by increasing the secretion of growth hormone (GH) and insulin-like growth factor (IGF-1).

According to the instructions, anamorelin is mainly suitable for the following types of patients:

1. Cancer cachexia patients: Applicable to cachexia symptoms such as loss of appetite and weight loss caused by unresectable advanced or recurrent non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer, etc.

2. Patients with no obvious effect of nutritional therapy: For patients whose weight loss cannot be improved after nutritional supplements, intravenous nutrition or oral nutritional preparations, anamorelin can be used as an auxiliary drug treatment.

3. Cachexia patients who meet the diagnostic criteria: including weight loss of more than 5% in the past 6 months, accompanied by two or more symptoms, such as:

Persistent fatigue or general feeling of lethargy;

Significant muscle weakness or reduced activity tolerance;

Abnormal inflammation and nutritional indicators (such asCRP>0.5mg/dL, Hb<12g/dL, albumin<3.2g/dL).

However, it should be noted that this drug is not suitable for patients who are unable to eat normally due to difficulty swallowing or malabsorption. Such people cannot obtain effective absorption after taking the drug.

2. [Recommended dosage and administration]

The recommended dose of anamorelin is 100mg once a dayorally on an empty stomach.

It is clinically recommended to take it after getting up in the morning and before breakfast to ensure the best absorption rate of the drug in the gastrointestinal tract. During the medication period, regular medication times should be maintained and avoid taking with high-fat meals, because high-fat foods may affect drug absorption. If you miss a dose, you should take it as soon as possible on the same day, but do not double the dose.

The drug is an oral formulation that can be used by patients under long-term outpatient management without the need for intravenous administration. Studies have shown that appetite improvement and weight gain trends can usually be observed within 1 to 2 weeks after taking anamorelin, which is especially obvious for patients with long-term cachexia.

3. [Adverse reactions and safety]

Although anamorelin is generally well tolerated, due to its effects on the cardiac conduction system and hepatic metabolism, close monitoring is required during use. Common adverse reactions include:

1. Electrocardiogram abnormalities: Prolonged PR interval or QRS interval, prolonged QT interval, and a few patients may develop atrioventricular block, bradycardia or premature supraventricular contractions;

2. Cardiovascular symptoms: Some patients may experience palpitations, mild tachycardia or decreased blood pressure;

3. Reactions related to digestion and metabolism: such as dry mouth, frequent urination, mild water retention, etc.;

4. Elevation of liver function indicators: Some patients experience an increase inAST, ALT, ALP or γ-GTP, and rarely accompanied by an increase in bilirubin.

Doctors should assess the risk based on the patient's underlying disease and electrocardiogram when prescribing. Patients with arrhythmia, history of QT prolongation or abnormal liver function should be used with caution. If significant ECG changes or liver enzyme elevations occur, medication should be suspended and monitored.

4. [Pharmacological mechanism of action]

Anamulin simulates the effect of the natural hunger hormone in the bodyGhrelin, binds to and activates the GHS-R1a receptor, thereby achieving multiple physiological effects:

1. Promote appetite: By stimulating the arcuate nucleus neurons of the hypothalamus, it enhances hunger signals and improves the lack of appetite in cancer patients.

2. Increase the secretion of growth hormone: Stimulate the secretion of pituitary glandGH, promote protein synthesis and muscle formation, and help patients recover their physical strength.

3. Improve nutritional metabolism: by increasingIGF-1 levels and fat utilization lead to a gradual increase in body weight and muscle mass.

4. Anti-inflammatory and anti-catabolic effects: In some studies, anamulin has shown the potential effect of reducing the levels of inflammatory factors and helping to delay the process of muscle wasting.

This makes anamorelin one of the key drugs in the supportive care of cancer. Unlike traditional nutritional therapy or steroid preparations, it can systematically improve cachexia symptoms from a neuroendocrine level.

5. [Storage and use precautions]

Anamorelin should be stored at room temperature, away from direct sunlight and high temperature and humidity. Tablets must be kept dry and sealed to prevent children from accidentally swallowing them.

During the medication period, patients are advised to follow a high-protein diet and moderate exercise to maximize the efficacy. At the same time, doctors should regularly monitor weight changes, blood biochemical indicators and electrocardiogram conditions. Dosage adjustments should be made with caution in patients at risk for cardiac arrhythmias.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/